Active, not recruitingNCT00005902
Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
Studying Von Hippel-Lindau disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Principal Investigator
- Prashant Chittiboina, M.D., MDNational Institute of Neurological Disorders and Stroke (NINDS)
- Enrollment
- 250 enrolled
- Eligibility
- 8-75 years · All sexes
- Timeline
- 2001
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005902 on ClinicalTrials.govOther trials for Von Hippel-Lindau disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07171905CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau DiseaseIRCCS Ospedale San Raffaele
- ENROLLING BY INVITATIONNANCT05737602Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau DiseaseMassachusetts General Hospital
- RECRUITINGPHASE2NCT07167329Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialJosé Claudio Casali da Rocha
- RECRUITINGNCT05955014Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center
- RECRUITINGNCT06194669Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule CellsIRCCS San Raffaele
- RECRUITINGNANCT05424016Propranolol and Von Hippel-Lindau DiseaseAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Merck Sharp & Dohme LLC